Type 2 diabetes
Item
subjects with type 2 diabetes for more than 2 years
boolean
C0011860 (UMLS CUI [1])
insulin glargine
Item
subjects currently treated with unchanged insulin glargine dose (10 -100 units) for 2 weeks
boolean
C0907402 (UMLS CUI [1])
oral anti-diabetic drugs
Item
subjects currently treated with unchanged dose(s) for at least 1 month on one or two oral anti-diabetic drugs
boolean
C0359086 (UMLS CUI [1])
BMI
Item
bmi 25 - 40 kg/m2
boolean
C1305855 (UMLS CUI [1])
HbA1C
Item
hba1c < 9.5 %
boolean
C0202054 (UMLS CUI [1])
allergy to trial product(s) or related products
Item
known or suspected allergy to trial product(s) or related products
boolean
C0020517 (UMLS CUI [1,1])
C0907402 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0123677 (UMLS CUI [2,2])
previous randomisation in this trial
Item
previous randomisation in this trial
boolean
C2348568 (UMLS CUI [1])
pregnancy, breast-feeding, intention of becoming pregnant or pre-menopausal women judged not to be using adequate contraceptive measures
Item
pregnancy, breast-feeding, intention of becoming pregnant or pre-menopausal women judged not to be using adequate contraceptive measures (only sterilisation, intra uterine devices and contraceptive pills are considered adequate contraceptive methods)
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C2081645 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
mental incapacity, unwillingness or language barriers precluding adequate understanding and co-operation
Item
mental incapacity, unwillingness or language barriers precluding adequate understanding and co-operation.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
other significant illness
Item
any other significant illness such as endocrine, cardiac, neurological, malignant or other pancreatic illness judged by investigator
boolean
C0009488 (UMLS CUI [1])
participation in other studies
Item
participation in other studies within the last three months
boolean
C2348568 (UMLS CUI [1])